Decellularized Extracellular Matrix (ECM)
Decellularization removes cellular material from donor tissue to produce an extracellular-matrix scaffold. Sources include human allografts and animal tissues. Processing aims to retain useful matrix structure and signals, but does not guarantee removal of every antigen, preservation of all native components or absence of an immune response.[1][2]
What the scaffold provides
A matrix can support host-cell attachment and ingrowth. The result depends on its source, processing, residual cellular or chemical material, mechanical properties and recipient tissue. Remodeling may produce useful tissue, but can also lead to inflammation, fibrosis, contracture or failure. A scaffold derived from bladder does not automatically regenerate a functional bladder.[2][3]
Common sources include porcine small intestinal submucosa (SIS), bladder matrix, dermal matrix and human donor tissues. These are not interchangeable products: thickness, layering, processing and intended use matter.
Urethral reconstruction
EAU guidance distinguishes cell-free matrices from cultured oral-mucosa grafts. It advises against cell-free grafts with extensive spongiofibrosis, previous failed urethroplasty or strictures longer than 4 cm (weak recommendation). Cultured autologous oral-mucosa grafts should be used only within clinical trials (strong recommendation). These are separate categories; neither recommendation establishes routine superiority over native oral mucosa.[4]
Bladder and ureteral replacement
Promising cell-culture and animal findings, and selected human reports, have not established a dependable general replacement for conventional urinary reconstruction. A successful small patch in a healthy animal does not demonstrate that a long tube or large reservoir will remain vascularized, watertight and functional in scarred human tissue.[2][3]
Commercial availability of an ECM wound or soft-tissue product does not itself establish a urinary-organ replacement indication. Identify the exact product, indication and applicable evidence. For established bowel-based options and their limitations, see Bowel Segments.
Practical interpretation
Look for the actual defect repaired, cell-free versus cell-seeded design, vascular bed, follow-up duration and functional endpoints. Histology or epithelial coverage alone cannot establish durable patency, low-pressure storage, continence or renal protection. Processing and laboratory biocompatibility are necessary considerations, not proof of clinical success.[2][3]
References
1. Davis NF, Cunnane EM, Quinlan MR, et al. Biomaterials and Regenerative Medicine in Urology. Advances in Experimental Medicine and Biology. 2018;1107:189–198. doi:10.1007/5584_2017_139
2. Duan L, Wang Z, Fan S, Wang C, Zhang Y. Research Progress of Biomaterials and Innovative Technologies in Urinary Tissue Engineering. Frontiers in Bioengineering and Biotechnology. 2023;11:1258666. doi:10.3389/fbioe.2023.1258666
3. Sharma S, Basu B. Biomaterials Assisted Reconstructive Urology: The Pursuit of an Implantable Bioengineered Neo-Urinary Bladder. Biomaterials. 2022;281:121331. doi:10.1016/j.biomaterials.2021.121331
4. European Association of Urology. EAU Guidelines on Urethral Strictures. 2026. Chapter 9: Tissue transfer. Guideline text and recommendations.
See also: Synthetic Polymer Scaffolds, Composite Scaffolds, Bowel Segments.